Anti-Human CTLA-4 (Ipilimumab) – Fc Muted™ Biotin
Anti-Human CTLA-4 (Ipilimumab) – Fc Muted™ Biotin
Product No.: LT1606
- -
- -
Product No.LT1606 Clone MDX-010 Target CTLA-4 Product Type Biosimilar Recombinant Human Monoclonal Antibody Alternate Names CD; GSE; GRD4; ALPS5; CD152; CTLA-4; IDDM12; CELIAC3 Isotype Human IgG1κ Applications ELISA , FC |
- -
- -
Antibody DetailsProduct DetailsReactive Species Human Host Species Human Expression Host HEK-293 Cells FC Effector Activity Muted Immunogen Human CTLA-4 Product Concentration 0.5 mg/ml Formulation This Biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. Storage and Handling This biotinylated antibody is stable when stored at 2-8°C. Do not freeze. Regulatory Status Research Use Only (RUO). Non-Therapeutic. Country of Origin USA Shipping Next Day 2-8°C RRIDAB_2893923 Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for Ipilimumab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. ELISA Additional Reported Applications For Relevant Conjugates ? B CyTOF® Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Ipilimumab. Ipilimumab binds to Human CTLA-4. This product is for research use only. Background Cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) is a protein receptor that serves as an immune checkpoint and down-regulates the immune system. CTLA-4 is constitutively expressed in regulatory T cells but is only upregulated in conventional T cells following activation. Many cancers, including Melanoma, are associated with CTLA-4 upregulation because the body’s ability to recognize and destroy cancer cells is hampered by an inhibitory mechanism. Ipilimumab targets CTLA-4 and works by turning off this inhibitory mechanism and, thus, enhances the body’s own immune response against cancer cells.”2 Emerging research suggests that combined blockade of PD-1 and CTLA-4, with Nivolumab and Ipilimumab respectively, could produce greater antitumor activity than blockade of either pathway alone.1 This cost-effective, research-grade Anti-Human CTLA-4 (Ipilimumab) utilizes the same variable regions from the therapeutic antibody Ipilimumab making it ideal for research projects. Antigen Distribution CTLA4 is constitutively expressed in regulatory T cells. PubMed NCBI Gene Bank ID UniProt.org Research Area Biosimilars . Immunology . Inhibitory Molecules References & Citations1. Wolchok, JD. et al. (2013) N Engl J Med 369(2):122-33. 2. Soo, RA. et al. (2017) Lancet Oncol. 18(12):e731-e741. 3. Lipson, EJ. and Drake, CG. (2011) Clin Cancer Res 17(22):6958-62. Technical Protocols  Certificate of Analysis |
Formats Available
- -
- -
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
